News & Updates

Show Multimedia Only

Balloon size and radiotherapy history increase restenosis risk after carotid artery stenting

02 Sep 2026 by

Researchers at the University of Hong Kong (HKU) found that the 12-month restenosis rate after carotid artery stenting (CAS) is about 26.3 percent, with a history of radiotherapy and post-dilatation balloon diameter being associated with higher restenosis risk, but restenosis rarely caused new neurological events.

Balloon size and radiotherapy history increase restenosis risk after carotid artery stenting

02 Sep 2026

Original New Drug Application Approvals by US FDA (16-31 July 2026)

02 Sep 2026

New drug applications approved by US FDA as of 16-31 July 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 July 2026)

02 Sep 2026

SGLT2i & GLP-1 RA may protect against Parkinson’s disease

02 Sep 2026 by

Antidiabetic drugs may exert effects beyond glycaemic control and could influence neurodegenerative risk, with sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) being associated with lower risk of Parkinson’s disease (PD), suggesting potential neuroprotective effects, a Bayesian network meta-analysis has found.

SGLT2i & GLP-1 RA may protect against Parkinson’s disease

02 Sep 2026

Doravirine-based ART matches dolutegravir-based regimen in efficacy with less weight gain

01 Sep 2026 by

Among treatment-naïve adults with HIV who are initiating antiretroviral therapy (ART), a regimen containing doravirine, lamivudine, and tenofovir disoproxil fumarate (DOR/3TC/TDF) is as good as the dolutegravir, emtricitabine, and tenofovir alafenamide (DTG/FTC/TAF) regimen in terms of viral suppression but is associated with less weight gain, according to the open-label, head-to-head OPTI-DOR study conducted in South Africa.

Doravirine-based ART matches dolutegravir-based regimen in efficacy with less weight gain

01 Sep 2026

Weight loss medications rarely prescribed in patients with MASLD: study

01 Sep 2026

A survey conducted prior to resmetirom approval reports low rates of weight loss medication prescription due to low comfort potentially from lack of education despite strong beliefs that these drugs can benefit patients with metabolic dysfunction-associated steatotic liver disease (MASLD).

Weight loss medications rarely prescribed in patients with MASLD: study

01 Sep 2026

Patients who underwent gender-affirming surgery report satisfaction, reduced distress

01 Sep 2026

Patient satisfaction is high during the first year following penile inversion vaginoplasty for functional outcomes and alleviation of gender dysphoria, a study has shown.

Patients who underwent gender-affirming surgery report satisfaction, reduced distress

01 Sep 2026

No link between prenatal organophosphate pesticide exposure and autism-related traits in childhood

01 Sep 2026

Prenatal exposure to organophosphate pesticides does not appear to contribute to an increased likelihood of having autism-related traits in childhood, according to a study.

No link between prenatal organophosphate pesticide exposure and autism-related traits in childhood

01 Sep 2026

Atogepant tied to better outcomes in adults with migraine

01 Sep 2026 by

In a subgroup of patients with migraine who completed the full 24-week double-blind treatment period, referred to as treatment completers, treatment with atogepant is associated with greater improvements in clinical efficacy and functional endpoints than topiramate, according to a post hoc analysis of the TEMPLE trial presented at EAN 2026.

Atogepant tied to better outcomes in adults with migraine

01 Sep 2026

Intensified triplet regimens may improve PFS in mHSPC

01 Sep 2026 by

First-line combination treatment with docetaxel plus androgen receptor pathway inhibitor (ARPI) plus androgen deprivation therapy (ADT) or poly(ADP-ribose) polymerase inhibitor (PARPi) plus ARPI plus ADT results in clinically relevant but not statistically significant improvements in progression-free survival (PFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC), a study has found.

Intensified triplet regimens may improve PFS in mHSPC

01 Sep 2026

Tenofovir-sparing ART carries HBV risks

31 Aug 2026 by

Discontinuing tenofovir in antiretroviral therapy (ART) may expose people living with HIV to hepatitis B virus (HBV)-related risks, including reactivation in those previously exposed and infection in those who are susceptible, according to a systematic review and meta-analysis.

Tenofovir-sparing ART carries HBV risks

31 Aug 2026

News & Updates

Showing Multidisciplinary articles

Showing

Specialty:

Balloon size and radiotherapy history increase restenosis risk after carotid artery stenting

Balloon size and radiotherapy history increase restenosis risk after carotid artery stenting

Original New Drug Application Approvals by US FDA (16-31 July 2026)

Original New Drug Application Approvals by US FDA (16-31 July 2026)

SGLT2i & GLP-1 RA may protect against Parkinson’s disease

SGLT2i & GLP-1 RA may protect against Parkinson’s disease

Doravirine-based ART matches dolutegravir-based regimen in efficacy with less weight gain

Doravirine-based ART matches dolutegravir-based regimen in efficacy with less weight gain

Weight loss medications rarely prescribed in patients with MASLD: study

Weight loss medications rarely prescribed in patients with MASLD: study

Patients who underwent gender-affirming surgery report satisfaction, reduced distress

Patients who underwent gender-affirming surgery report satisfaction, reduced distress

No link between prenatal organophosphate pesticide exposure and autism-related traits in childhood

No link between prenatal organophosphate pesticide exposure and autism-related traits in childhood

Atogepant tied to better outcomes in adults with migraine

Atogepant tied to better outcomes in adults with migraine

Intensified triplet regimens may improve PFS in mHSPC

Intensified triplet regimens may improve PFS in mHSPC

Tenofovir-sparing ART carries HBV risks

Tenofovir-sparing ART carries HBV risks